32 results
F-1
SPRC
SciSparc Ltd
27 Feb 24
Registration statement (foreign)
4:15pm
“-Committees of the Board of Directors-Internal Auditor” below.
Leadership Structure of the Board of Directors
In accordance with the Companies Law and our
6-K
EX-99.1
SPRC
SciSparc Ltd
16 Jun 23
Report of Foreign Private Issuer
9:09am
of Jerusalem, under the leadership of Prof. Tam, included multi-parameter metabolic assessments such as body weight, fat mass, glucose tolerance
6-K
EX-99.1
SPRC
SciSparc Ltd
2 Jun 23
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
9:04am
, Tolerability and Efficacy Trend of SCI-110 in Patients with Alzheimer’s Disease and Agitation,” was conducted at the IMCA under the leadership of Dr
6-K
EX-99.1
SPRC
SciSparc Ltd
2 May 23
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer’s Disease and Agitation
7:28am
and Agitation” is being conducted at The Israeli Medical Center for Alzheimer’s under the leadership of Dr. Alexander Kaplan, MD, principal
6-K
EX-99.1
4wj4oi5l x54isziiep6
4 Apr 23
SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
5:48pm
6-K
EX-99.1
rb2gn78nszieyubaw
8 Nov 22
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
7:33am
6-K
EX-99.1
r3at5oox8 czre2lz4
11 Aug 22
Current Report
4:05pm
6-K
EX-99.1
tgk2 x11ybaxgw1
22 Feb 22
Report of Foreign Private Issuer
9:05am
6-K
EX-99.1
0jetmhvn
29 Dec 21
SciSparc Provides Updates Upon Conclusion of 2021
5:12pm
6-K
EX-99.1
qiori08yrtr57 weko7m
20 Dec 21
SciSparc Announces Approval of Uplisting to The Nasdaq Capital Market
4:45pm
6-K
EX-99.1
kbfslz
7 Jul 21
Current Report of Private Issuer
4:00pm
6-K
EX-99.1
htwhu4a dlg5anj3y3
17 Feb 21
Report of Foreign Private Issuer
8:35am
6-K
EX-99.1
xcv5un9khu iif5g
2 Dec 20
Therapix Biosciences to Collaborate with The University of Calgary to Further Examine its Proprietary Drug Candidate THX-160 for Pain
9:25am
6-K
EX-99.1
m6v4pafxva5 3e2vvl0
8 May 20
Therapix Biosciences Appoints Prof. Ari Shamiss (M.D., M.P.A.) to the Company’s Board of Directors
6:04am
6-K
EX-99.1
rfk97pvgd34tqtrdwgt
22 Apr 20
Therapix Biosciences Announces Appointment of New CEO
5:30pm